{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:49Z","timestamp":1786649869337,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The most common subtype of aggressive non-Hodgkin Lymphomas is diffuse large B-cell lymphoma (DLBCL). Mediastinal DLBCL is a distinct entity with unique clinical, pathologic, and genetic features and accepted as a subtype of DLBCL. The aim of this study is to evaluate the patients treated with consolidative radiotherapy (RT) after rituximab-containing chemotherapy for mediastinal DLBCL regarding treatment outcomes and relapse patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>Forty-two patients with the diagnosis of mediastinal DLBCL who were treated at the Ege University Hospital between January 2008 and December 2014 were evaluated. All patients received 2\u201310 cycles of rituximab-containing chemotherapy schedule (mostly CHOP). RT was delivered to a total dose of 30.6\u201345 Gy with 1.8 Gy daily fractions in 4\u20135 weeks. The irradiation fields were designed by using involved lymphatic site technique.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median age at diagnosis was 53 years (range, 18\u201385 years). Ann Arbor clinical stage at diagnosis was as follows: 8 patients (19%) at Stage I, 20 patients (47.6%) at Stage II, 7 patients (16.7%) at Stage III, and 7 patients (16.7%) at Stage IV. The median follow-up period was 47 months (range, 7\u201396 months). Complete response was obtained in 27 patients (64.3%), partial response was obtained in 14 patients (33.3%) across all stages. Estimated 5-year overall survival (OS) and progression-free survival (PFS) rates were, respectively, 84% and 77% for all patients, 100% and 92% for the patients without residual disease after chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The response to chemotherapy is the most important factor affecting both OS and PFS. The role of consolidative RT is not clear in the rituximab era due to the lack of phase III trial. However, available literature shows that consolidative RT may still have a role in mediastinal DBLCLs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_3_17","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:03:38Z","timestamp":1531991018000},"page":"1397-1402","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era"],"prefix":"10.4103","volume":"14","author":[{"given":"Fatma","family":"Sert","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Ege University Medical Faculty, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serra","family":"Kamer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ege University Medical Faculty, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcray","family":"Saydam","sequence":"additional","affiliation":[{"name":"Department of Hematological Oncology, Ege University Medical Faculty, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Anacak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ege University Medical Faculty, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/sj.leu.2403096","article-title":"Current trends in large cell lymphoma","volume":"17","author":"Fisher","year":"2003","journal-title":"Leukemia"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.6004\/jnccn.2012.0155","article-title":"Non-Hodgkin's lymphomas, version 3.2012","volume":"10","author":"Zelenetz","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 7","key":"R4-20260109","doi-asserted-by":"crossref","first-page":"vii78","DOI":"10.1093\/annonc\/mds273","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Tilly","year":"2012","journal-title":"Ann Oncol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.ijrobp.2008.02.068","article-title":"Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: A surveillance, epidemiology, and end results analysis","volume":"72","author":"Ballonoff","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","article-title":"Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy","volume":"28","author":"Phan","year":"2010","journal-title":"J Clin Oncol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMoa042040","article-title":"ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma","volume":"352","author":"Reyes","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","article-title":"Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern cooperative oncology group study 1484","volume":"22","author":"Horning","year":"2004","journal-title":"J Clin Oncol"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","article-title":"CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the groupe d'Etude des lymphomes de l'Adulte","volume":"25","author":"Bonnet","year":"2007","journal-title":"J Clin Oncol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3109\/10428194.2011.585526","article-title":"Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma","volume":"52","author":"Marcheselli","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.29113","article-title":"Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the national comprehensive cancer network lymphoma outcomes project","volume":"121","author":"Dabaja","year":"2015","journal-title":"Cancer"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/10428190410001667712","article-title":"Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome","volume":"45","author":"Avil\u00e9s","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0360-3016(94)90352-2","article-title":"Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma","volume":"30","author":"Avil\u00e9s","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014","volume":"26","author":"Persky","year":"2008","journal-title":"J Clin Oncol"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J Clin Oncol"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2011.12.067","article-title":"Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging","volume":"84","author":"Dorth","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijrobp.2013.02.007","article-title":"Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy","volume":"86","author":"Shi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-012-1602-3","article-title":"Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma","volume":"92","author":"Miyazaki","year":"2013","journal-title":"Ann Hematol"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12185-011-0822-y","article-title":"High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma","volume":"93","author":"Chihara","year":"2011","journal-title":"Int J Hematol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201814060-00039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:19Z","timestamp":1786647559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201814060-00039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_3_17","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}